Our professionals

Dr. Jesús Corral

Specialist in Medical Oncology

Works at: Madrid headquarters
Be part of: Clínica Universidad de Navarra Cancer Center Universidad de Navarra

Professional career

Graduated in Medicine and Surgery. Faculty of Medicine. University of Seville in 2003.

Specialist in Medical Oncology at Hospital Universitario Virgen del Rocio, Seville in 2008.

MS Biomedical Research: Hospital Universitario Virgen del Rocío, University of Seville in 2007.

MS Clinical Trials: University of Seville in 2011.

Oncoavanze: Asistencia Oncológica Integral, Seville, 2015-2017.


He has participated in several research projects:

  • Experimental Clinical Study and systematic literature review of the efficacy and clinical impact of 18F-FDG-PET/TAC in the assessment of response to neoadjuvant chemotherapy in stage IIIA non-small cell lung cancer. Funding: 90000 euros /Consejería de Salud, Junta de Andalucia. Principal Investigator: Isabel Borrego Dorado.
  • miRNA and gene expression profile in non-small cell lung cancer: correlation with histology and prognosis in operable patients. (P08-CVI-4090) Funding: 167,500.00 euros / Proyectos de Excelencia - Consejería de Innovación, Ciencia y Empresa. Principal Investigator: Luis Paz-Ares.
  • Identification of biomarkers of drug sensitivity and resistance in an in vivo platform of human colon cancer xenografts (PI 10.02164). Funding: 256,520.00 euros/ Fondo de Investigaciones Sanitarias (FIS-ISCiii). Principal Investigator: R Garcia-Carbonero.
  • Phase I, single-center, randomized, open-label clinical trial to evaluate the effect of food (fasting and standard food) on the pharmacokinetic parameters of lapatinib at a reduced dose, versus lapatinib administered fasting at a conventional dose, in unresectable, locally advanced or metastatic HER2-positive breast cancer after progression to trastuzumab (PI-0777-2011). Funding: 39,939 euros/ Consejería de Salud, Junta de Andalucia. Principal Investigator: Jesús Corral
  • Detection of the T790M mutation by ultrasensitive PCR method prior to treatment with EGFR tyrosine kinase inhibitors (TKI) as a predictor of the mechanism of resistance to progression in patients with stage IV non-small cell lung carcinoma (NSCLC) and EGFR mutation. Funding: 60000 euros / Conselleria de Sanitat Universal i Salut Pública. Hospital Universitario y Politécnico de La Fe, Valencia. Principal Investigator: Óscar Juan Vidal.


As an educator

Associate Professor, MS applied clinical research in oncology. Universidad San Pablo-CEU-Hospital Universitario Sanchinarro, Madrid 2014-2017.

Associate Professor of Medical Oncology at the University of Seville, 2013-2017.

Consultant in Medical Oncology. Thoracic Oncology and New Drugs Development Program Medical Oncology Department. Virgen del Rocio University Hospital, Seville, 2012-2017.

As a researcher

He has participated in the elaboration of more than 20 scientific publications in national and international journals and as co-author of 10 chapters of books in his specialty.

He has presented more than 30 posters and communications in national and international congresses.


  • First Merit Award of the “Sociedad Andaluza de Cancerología”. Jaen, 2006.
  •  First Merit Award of the 3rd Congress “Hitos Oncológicos”. Madrid, 2008.
  •  First Merit Award to the best fellowship in Hospital Universitario Virgen del Rocío. Seville, 2008.
  •  Scholar, 11th ECCO-AACR-ASCO Workshop. “Methods in Clinical Cancer Research”.  Flims, 2009.
  •  INC Clinical Research Award. Phase I Unit Hospital Universitario Virgen del Rocío, Seville, 2015.
  •  First Merit Award of the 1st Workshop of Young Investigators in Lung Cancer. Madrid, 2015.
  • Third Merit Award of the “Concurso de Experiencias Clínicas en Dolor Irruptivo en Oncología Médica”. Madrid, 2016.

Latest scientific publications